1380088-64-1

Basic information

• Product Name: (2R)-2-((6S)-4-(4-cyanophenyl)-2,3,9-trimethyl-6H-isoxazolo[5,4-c]thieno[2,3-e]azepin-6-yl)propanamide
• CAS NO: 1380088-64-1
• Molecular Weight: 404.492
• Mol File: 1380088-64-1.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: (2R)-2-((6S)-4-(4-cyanophenyl)-2,3,9-trimethyl-6H-isoxazolo[5,4-c]thieno[2,3-e]azepin-6-yl)propanamide(CAS DataBase Reference)
• NIST Chemistry Reference: (2R)-2-((6S)-4-(4-cyanophenyl)-2,3,9-trimethyl-6H-isoxazolo[5,4-c]thieno[2,3-e]azepin-6-yl)propanamide(1380088-64-1)
• EPA Substance Registry System: (2R)-2-((6S)-4-(4-cyanophenyl)-2,3,9-trimethyl-6H-isoxazolo[5,4-c]thieno[2,3-e]azepin-6-yl)propanamide(1380088-64-1)

Safety Data

• Hazardous Substances Data: 1380088-64-1(Hazardous Substances Data)

Upstream product

• 1380090-30-1 (2R)-tert butyl 2-((6S)-2,3,9-trimethyl-4-oxo-5,6-dihydro-4H-isoxazolo[4,5-e]thieno[3,2-c]azepin-6-yl)propanoate 
• 1448631-48-8 methyl 2-(5-((S)-3-(tert-butoxy)-1-((S)-1,1-dimethylethylsulfinamido)-3-oxopropyl)-3-methylisoxazol-4-yl)-4,5-dimethylthiophene-3-carboxylate 
• 1448631-46-6 methyl 2-(5-(hydroxymethyl)-3-methylisoxazol-4-yl)-4,5-dimethylthiophene-3-carboxylate 
• 1472673-29-2 (1S)-3-(tert-butoxy)-1-(4-(3-(methoxycarbonyl)-4,5-dimethylthiophen-2-yl)-3-methylisoxazol-5-yl)-3-oxopropan-1-aminium chloride 
• 1448631-51-3 methyl 2-(5-formyl-3-methylisoxazol-4-yl)-4,5-dimethylthiophene-3-carboxylate 
• 1380089-34-8 (3-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isoxazol-5-yl)methyl acetate 
• 1380089-33-7 (4-bromo-3-methyl-1,2-oxazol-5-yl)methyl acetate 
• 14559-13-8 methyl 4,5-dimethylthiophene-3-carboxylate 
• 1019115-42-4 methyl 2-bromo-4,5-dimethylthiophene-3-carboxylate 

Relevant articles and documents

Discovery, design, and optimization of isoxazole azepine BET inhibitors

The identification of a novel series of small molecule BET inhibitors is described. Using crystallographic binding modes of an amino-isoxazole fragment and known BET inhibitors, a structure-based drug design effort lead to a novel isoxazole azepine scaffold. This scaffold showed good potency in biochemical and cellular assays and oral activity in an in vivo model of BET inhibition.